Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aspirin and migraines

This article was originally published in The Tan Sheet

Executive Summary

Acetysalicylic acid is as effective as the Rx medication sumatriptan in relieving both migraine headaches and their symptoms, according to two studies presented in association with the Aspirin Award 2003 meeting in Fiuggi, Italy, Sept. 12. Approximately 312 patients were randomized to take two tablets of Bayer's effervescentAspirin Migraine (1,000 mg ASA), 50 mg sumatriptan, 400 mg ibuprofen or placebo. After two hours, "headaches were less severe or had disappeared altogether" in 52.2% of patients taking aspirin, Bayer states. Ibuprofen and sumatriptan both demonstrated similar effects. The second study found that two hours after administration, almost 44% of patients in the aspirin arm "were free of accompanying symptoms." Bayer was given the go-ahead to market Aspirin Migraine containing 500 mg ASA per tablet in October 2001, but has yet to market the product (1"The Tan Sheet" Nov. 5, 2001, p. 12)...

You may also be interested in...

Bayer Aspirin Migraine Gets FDA Nod; Midol May Be On Deck

Bayer is expanding the scope of its eponymous aspirin brand from heart attack and stroke prevention to migraine pain

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts